Infections Caused by Carbapenem-Resistant Enterobacteriaceae : An Update on Therapeutic Options

• Published in: Frontiers in microbiology 2019-01, Vol.10, p.80-80
• Main Authors: Sheu, Chau-Chyun, Chang, Ya-Ting, Lin, Shang-Yi, Chen, Yen-Hsu, Hsueh, Po-Ren
• Format: Article
• Language: English
• Subjects: avibactam; carbapenem-resistant Enterobacteriaceae; carbapenemase; carbapenems; combination therapy; Microbiology; relebactam
• ISSN: 1664-302X; 1664-302X
• DOI: 10.3389/fmicb.2019.00080

Carbapenems are considered as last-resort antibiotics for the treatment of infections caused by multidrug-resistant Gram-negative bacteria. With the increasing use of carbapenems in clinical practice, the emergence of carbapenem-resistant pathogens now poses a great threat to human health. Currently, antibiotic options for the treatment of carbapenem-resistant (CRE) are very limited, with polymyxins, tigecycline, fosfomycin, and aminoglycosides as the mainstays of therapy. The need for new and effective anti-CRE therapies is urgent. Here, we describe the current understanding of issues related to CRE and review combination therapeutic strategies for CRE infections, including high-dose tigecycline, high-dose prolonged-infusion of carbapenem, and double carbapenem therapy. We also review the newly available antibiotics which have potential in the future treatment of CRE infections: ceftazidime/avibactam, which is active against KPC and OXA-48 producers; meropenem/vaborbactam, which is active against KPC producers; plazomicin, which is a next-generation aminoglycoside with activity against CRE; and eravacycline, which is a tetracycline class antibacterial with activity against CRE. Although direct evidence for CRE treatment is still lacking and the development of resistance is a concern, these new antibiotics provide additional therapeutic options for CRE infections. Finally, we review other potential anti-CRE antibiotics in development: imipenem/relebactam and cefiderocol. Currently, high-dose and combination strategies that may include the new β-lactam/β-lactamase inhibitors should be considered in severe CRE infections to maximize treatment success. In the future, when more treatment options are available, therapy for CRE infections should be individualized and based on molecular phenotypes of resistance, susceptibility profiles, disease severity, and patient characteristics. More high-quality studies are needed to guide effective treatment for infections caused by CRE.